Imprimis Pharmaceuticals Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Rayno Small Cap Biopharmaceutical Portfolio 2015 In Rally Mode - XBI Up 2.5%
Article By: Rod Raynovich
Tuesday, December 29, 2015 9:44 PM EDT
We recommended three new small caps at the October Bioinvestor Forum: Curis, Geron and Ocera Therapeutics. This forum offers the best window on emerging small companies in the fall, a good time to get a head start on biotech small cap investing.
In this article: ARRY, CRIS, GERN, XBI, IMMY, GLYC, FCSC, RXDX, OCRX
Read
Novartis Comes Under Fire: Consider Newer Startup Imprimis Instead
Article By: Don Dion
Wednesday, December 2, 2015 9:33 AM EDT
Novartis, like other major pharmaceutical companies, has recently come under fire for drastically increasing the prices of drugs. Drug companies are facing a major public and political backlash.
In this article: NVS, IMMY
Read
Rayno Small Caps Outperform: New Long Idea - Imprimis Pharmaceuticals
Article By: Rod Raynovich
Tuesday, December 1, 2015 7:00 PM EDT
Today we added a new small cap speculative pick, Imprimis Pharmaceutical, an emerging pharmaceutical Company focused on developing and commercializing proprietary compounded, customized drug therapies to physicians and patients in the US.
In this article: ARRY, CRIS, GERN, IMMY, GLYC, FCSC, RXDX
Read
Imprimis: A Miracle Or Just A Press Release?
Article By: Wall Street Daily
Sunday, October 25, 2015 4:54 PM EDT
Imprimis Pharmaceuticals Inc. is offering an alternative to Turing’s pill at the low, low price of just $1 each, and is also creating an entire program dedicated to getting other overpriced, off-patent drugs into patients’ hands at lower prices.
In this article: IMMY
Read
Imprimis' Platform Set To Bring Library Drug Formulations Quickly To Market
Article By: M.E. Garza
Friday, May 30, 2014 12:00 PM EDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has seen its stock rise from about $5.25 per share in February at the time of the NASDAQ listing to around $9 per share and is one of the best performing stocks in the biotech industry this year.
In this article: IMMY
Read

Latest Tweets for $IMMY

No tweets yet!

PARTNER HEADLINES